Danimer Scientific Announces Proposed Pro-Rata Distribution of Warrants to Purchase Common Stock

Bainbridge, Georgia – May 2, 2024 – Danimer Scientific, Inc. (NYSE: DNMR) (“Company” or “Danimer Scientific”), a leading next generation bioplastics company focused on the development and production of biodegradable materials, today announced a proposed pro-rata dividend distribution of warrants (“Dividend Warrants”) to holders of the Company’s Class A Common Stock, par value $0.0001 per share (“Common Stock”) as of May 13, 2024 (“Record Date”). Subject to the Company’s stockholders approving a proposal to increase the authorized number of shares of the Company’s Common Stock under the Company’s Fourth Amended and Restated Certificate of Incorporation at the Company’s upcoming annual meeting of stockholders to be held on or about July 9, 2024, the stockholders of record as of the Record Date will receive one (1) Dividend Warrant for each three (3) shares of Common Stock held as of the Record Date, subject to downward rounding. Holders of our 3.250% Convertible Senior Notes due 2026 (“Convertible Notes”) and our pre-funded common stock purchase warrants dated March 25, 2024 (collectively, “other eligible recipients”) as of the Record Date will also receive Dividend Warrants on a pass-through basis as determined in the agreements governing such securities and the warrant agreement governing the Dividend Warrants. The Company expects to distribute the Dividend Warrants to stockholders and other eligible recipients on or about July 12, 2024 (the date of such distribution, the “Distribution Date”). In the event that the Company’s stockholders do not approve the proposal to increase the authorized number of shares of Common Stock, no dividend will be issued.

After the Distribution Date, the Dividend Warrants are expected to list and trade on the OTCQX market, separate from Danimer Scientific’s Common Stock, which will continue to trade on the New York Stock Exchange. The holders of the Dividend Warrants may exercise the Dividend Warrants by using cash or, during the periods and in the manner specified in the warrant agreement, the Company’s outstanding Convertible Notes. The Dividend Warrants will include a provision that provides an additional one-half share of Common Stock to holders (“Bonus Share Fraction”) that exercise the Dividend Warrant prior to an expiration date that will be determined based upon certain trading criteria for the Company’s Common Stock.

Stephen E. Croskrey, Chairman and Chief Executive Officer of Danimer Scientific, commented, “Danimer is committed to improving balance sheet leverage, strengthening our capital structure and maximizing stockholder value. This distribution is the latest in a series of actions targeted to achieve those goals. It is structured to create a path for stockholders to capture value in a nondilutive warrant distribution. This deleveraging process would reward stockholders with warrants in proportion to their stockholdings and provide the opportunity for noteholders to participate in the transaction. This proposed transaction does not limit any other capital markets options for Danimer.”

Details of Warrant Distribution

If the Company’s stockholders vote to approve the proposal to increase the authorized number of shares of Common Stock, Stockholders will receive one (1) Dividend Warrant for each three (3) shares of Common Stock held as of the Record Date, rounded down to the nearest whole number for any fractional Dividend Warrant. As an example, a stockholder who owns 3,000 shares of Common Stock would receive 1,000 Dividend Warrants, and a stockholder who owns 1,000 shares of Common Stock would receive 333 Dividend Warrants. Each Dividend Warrant will entitle the holder to purchase, at the holder’s sole and exclusive election, one share of Common Stock plus, if applicable and as described below, the Bonus Share Fraction, at an initial exercise price of $5.00 per share. Other eligible recipients that hold Convertible Notes or pre-funded common stock purchase warrants as of the Record Date will receive Dividend Warrants based on the same ratio in the manner determined by the agreements governing such securities and the warrant agreement.

After the Distribution Date, Dividend Warrant holders may exercise their Dividend Warrants with cash or, after July 26, 2024, with the Company’s Convertible Notes at face value, as specified under the terms of the warrant agreement that is expected to be filed with the U.S. Securities and Exchange Commission (“SEC”) on the Distribution Date. For purposes of the Exercise Price, $1,000 principal amount of Convertible Notes shall be deemed to be equal to the aggregate Exercise Price in respect of 200 Dividend Warrants.

Any unredeemed Dividend Warrants will expire at 5:00 p.m. on the first anniversary of the Distribution Date (“Expiration Date”). The Dividend Warrants will be redeemable by the Company on or after August 1, 2024, upon twenty calendar days’ notice, from and after the first trading day following the date in which the daily volume weighted average price (“VWAP”) of the shares of Common Stock has been at least equal to a specified price, initially equal to the Exercise Price, for at least twenty trading days (whether or not consecutive) out of thirty consecutive trading days (“Redemption Price Condition”).

Details of Bonus Share Fraction

The Bonus Share Fraction feature referenced above would entitle a holder of a Dividend Warrant to receive an additional one-half of a share of Common Stock for each Dividend Warrant exercised under certain circumstances without payment of any additional exercise price. The right to receive the Bonus Share Fraction will expire at 5:00 p.m. New York City time on the first trading day following the date (“Bonus Share Expiration Date”) in which the daily VWAP of the shares of Common Stock has been at least equal to a specified price, initially $2.00 per share, for at least twenty trading days each falling on or after August 1, 2024 (whether or not consecutive) out of thirty consecutive trading days (“Bonus Share Expiration Price Condition”). Any Dividend Warrant exercised after the Bonus Share Expiration Date will not be entitled to the Bonus Share Fraction.

The Company will make a public announcement of the Bonus Share Expiration Date prior to market open on the Bonus Share Expiration Date in the case of a Bonus Share Expiration Price Condition is met.

Other Information

A Q&A regarding this proposed warrant distribution will be posted in the Investor Relations section of the Company’s website under the “Resources” tab, https://ir.danimerscientific.com/.

The distribution of the Dividend Warrants has not been registered under the Securities Act of 1933, as amended (“Securities Act”), because the issuance of a warrant for no consideration is not a sale or disposition of a security or interest in a security for value pursuant to Section 2(a)(3) of the Securities Act. The Company expects to file with the SEC a registration statement to register the shares of Common Stock underlying the Dividend Warrants.

B. Dyson Capital Advisors is serving as exclusive financial advisor on the Company’s distribution of the Dividend Warrants.

Gibson, Dunn & Crutcher LLP is serving as legal advisor to B. Dyson Capital Advisors.

Kane Kessler, P.C. is serving as legal advisor to the Company.

About Danimer Scientific

Danimer is a pioneer in creating more sustainable, more natural ways to make plastic products. For more than a decade, its renewable and sustainable biopolymers have helped create plastic products that are biodegradable and compostable and return to nature instead of polluting our lands and waters. Danimer’s technology can be found in a vast array of plastic end products that people use every day. Applications for its biopolymers include additives, aqueous coatings, fibers, filaments, films and injection-molded articles, among others. Danimer holds more than 480 granted patents and pending patent applications in more than 20 countries for a range of manufacturing processes and biopolymer formulations. For more information, visit https://danimerscientific.com.

No Offer or Solicitation

This Press Release and the Q&A referenced in it shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The proposed distribution of the Dividend Warrants is subject to and conditioned upon the Company’s stockholders first approving a proposal to increase the authorized number of shares of the Company’s Common Stock under its Fourth Amended and Restated Certificate of Incorporation at the Company’s upcoming annual meeting of stockholders to be held on or about July 9, 2024. Subsequently, a Form 8-A registration statement and prospectus supplement describing the terms of the Dividend Warrants will be filed with the Securities and Exchange Commission (“SEC”) and will be available on the SEC's website located at http://www.sec.gov. Holders of Common Stock and other eligible recipients should read the prospectus supplement carefully when it is filed, including the Risk Factors section included and incorporated by reference therein. This press release contains a general summary of the expected terms of the Dividend Warrants. The prospectus supplement and the warrant agreement, when filed, will describe the terms of the Dividend Warrants in more detail, and in the event of any inconsistency, the warrant agreement will govern the final terms of the Dividend Warrants. Please read the warrant agreement when it becomes available as it will contain important information about the terms of the Dividend Warrants.

Forward‐Looking Statements

Please note that in this press release we may use words such as “appears,” “anticipates,” “believes,” “plans,” “expects,” “intends,” “future,” and similar expressions which constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, statements regarding the outcome of stockholder votes on proposals at the Company’s annual meeting of stockholders. Forward-looking statements are made based on the Company’s expectations and beliefs concerning future events impacting the Company and therefore involve a number of risks and uncertainties. We caution that forward-looking statements are not guarantees and that actual results could differ materially from those expressed or implied in the forward-looking statements. Potential risks and uncertainties that could cause the actual results of operations or financial condition of the Company to differ materially from those expressed or implied by forward-looking statements in this release include, but are not limited to the Company’s expectations related to the use of proceeds from the equity offering; the overall level of consumer demand on the Company’s products; general economic conditions and other factors affecting consumer confidence, preferences, and behavior; disruption and volatility in the global currency, capital, and credit markets; the financial strength of the Company’s customers; the Company’s ability to implement its business strategy, including, but not limited to, its ability to expand its production facilities and plants to meet customer demand for its products and the timing thereof; risks relating to the uncertainty of the projected financial information with respect to the Company; the ability of the Company to execute and integrate acquisitions; changes in governmental regulation, legislation or public opinion relating to the Company’s products; the Company’s exposure to product liability or product warranty claims and other loss contingencies; the impact on the Company’s business, operations and financial results from the ongoing conflicts in Ukraine and the Middle East; the impact that global climate change trends may have on the Company and its suppliers and customers; the Company’s ability to protect patents, trademarks and other intellectual property rights; any breaches of, or interruptions in, the Company’s information systems; the ability of the Company’s information technology systems or information security systems to operate effectively, including as a result of security breaches, viruses, hackers, malware, natural disasters, vendor business interruptions or other causes; the Company’s ability to properly maintain, protect, repair or upgrade its information technology systems or information security systems, or problems with the Company’s transitioning to upgraded or replacement systems; the impact of adverse publicity about the Company and/or its brands, including without limitation, through social media or in connection with brand damaging events and/or public perception; fluctuations in the price, availability and quality of raw materials and contracted products as well as foreign currency fluctuations; the Company’s ability to utilize potential net operating loss carryforwards; and changes in tax laws and liabilities, tariffs, legal, regulatory, political and economic risks.